ArticleFrontiers in oncology2026
The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Brain metastases (BM) are highly prevalent in advanced non-small cell lung cancer (NSCLC); however, therapeutic options remain limited and suboptimal for driver gene-negative NSCLC BM patients. This study aimed to explore the efficacy and prognostic risk factors of brain radiotherapy combined with immunotherapy and chemotherapy in real-world for these patients. Methods: This study included 222 driver gene-negative NSCLC patients with BM. Inverse Probability of Treatment Weighting (IPTW) was employed to reduce the impact of selection bias and confounding factors. Prognostic risk factors were identified using Cox regression analysis. Survival outcomes were evaluated using Kaplan-Meier curves, and subgroup analyses were performed to explore the associations between treatment and survival results. Results: Based on the use of immunotherapy, patients were divided into the RT+CT+ICI group (received brain radiotherapy combined with immunotherapy and chemotherapy, n=117) and the RT+CT group (received brain radiotherapy combined with chemotherapy alone, n=105). The median overall survival (mOS) longer in the RT+CT+ICI group (19.6 vs. 15 months, Hazard Ratio [HR] 0.57, 95% confidence interval [CI] 0.41-0.79, Conclusions: This study demonstrates that brain radiotherapy combined with immunotherapy and chemotherapy is effective and predictive in driver gene-negative NSCLC BM patients. In addition, SRS and PD-L1 expression may be associated with better prognosis in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.